CA-OMNICELL
4.1.2021 14:02:10 CET | Business Wire | Press release
Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and supply chain solutions for health systems, today announced its intent to enter a new partnership with Guy’s and St Thomas’ NHS Foundation Trust, London to develop technology-enabled inventory optimization and intelligence services.
As part of a £10.5 million capital investment, the South East London Integrated Care System (ICS) will expand the deployment of Omnicell automation systems across six acute hospital sites. This also includes the opportunity for Omnicell and the Trust to launch a European-based technology-enabled intelligence center with the aim to deliver advanced analytics to manage supplies and medications. Combined with the expansion of Omnicell automated dispensing systems across the South East London hospitals, it is expected that this technology-enabled intelligence center will provide a high level of visibility and actionable insights for the South East London Integrated Care System to improve efficiency and patient safety.
The Integrated Care System includes two of the UK’s biggest hospital trusts, Guy’s and St Thomas’ NHS Foundation Trust and Kings College Hospital NHS Foundation Trust, as well as Lewisham and Greenwich NHS Trust. These Trusts are already using a mix of Omnicell’s XT supply and medication dispensing systems to manage clinical inventory and medications. The ICS successfully secured capital funding from the Department of Health Wave IV Estate Transformation Fund to undertake a regional supply chain transformation program.
By choosing Omnicell as its sole Inventory Management Solution, the Integrated Care System will be able to deliver consistency of practice and openly share data through a single instance based in the cloud. These systems, coupled with the expected technology-enabled intelligence centre based at Guy’s and St Thomas’, aim to provide total visibility of all medication and clinical inventory across the region. The solution will leverage the latest AI tools to provide real-time analytic support and system optimization. This will help reduce the risk of dispensing errors and help deliver the right medication, in the right place, at the right time.
Omnicell’s cloud-based intelligence, automation, and technology-enabled services are helping health systems across the globe to:
- support patient safety
- drive efficiencies
- reduce unnecessary and costly wastage
- allow healthcare professionals to increase their time for face-to-face patient care.
David Lawson, Chief Procurement Officer for Guy’s and St Thomas’, said: “We are delighted to join with Omnicell to bring this cutting-edge solution to the UK. The Trust has successfully deployed Omnicell systems for supplies and medication for over 10 years and the opportunity of this new intelligence offering alongside the expansion of Omnicell systems across South East London represents the next chapter in a successful long term partnership with Omnicell. Through this collaboration, South East London hopes to develop new AI tools to reduce variation between hospital sites and optimize system performance to allow for improved patient outcomes and operational efficiency at a regional level.”
Sara Dalmasso, vice president and general manager, International, at Omnicell said: “Expanding technology-enabled services and intelligence solutions reflects our ambition to deploy advanced analytic and optimization tools to support health systems across Europe. This new partnership with Guy’s and St Thomas’ also demonstrates that Omnicell is quickly becoming the go-to provider for regional medication and supply management solutions across the UK. We are hugely excited to be offered another opportunity to work with a likeminded partner who wants to reshape how automated inventory and medical supply management systems are viewed in the NHS and the wider European market. We share a goal of improving healthcare and patient safety, and I’m looking forward to working with Guy’s and St Thomas’ and South East London to support our joint vision.”
About Guy’s and St Thomas’ and South East London Integrated Care System
Guy’s and St Thomas’ provides 2.6 million patient contacts in acute and specialist hospital services and community services every year. As one of the biggest NHS trusts in the UK, with an annual turnover of almost £1.7 billion, we employ around 18,000 staff. To learn more, visit: www.guysandstthomas.nhs.uk
South East London Integrated Care System brings together local health and care organisations and local councils to re-design care and improve population health through shared leadership and collective action. It covers six London boroughs, Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark, with 1.9 million patients. Priorities include reducing costs through provider collaboration and changing the way they work together to deliver transformation. To learn more, visit: https://www.ourhealthiersel.nhs.uk/
About Omnicell
Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com .
OMCL-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005125/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo
Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 18:18:00 CEST | Press release
A global platform mobilizing expertise and collective action to advance shared digital priorities The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies an
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 18:00:00 CEST | Press release
- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms - Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease drive
Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders15.6.2026 17:30:00 CEST | Press release
For Boomi, this recognition reinforces its vision and momentum in enterprise agentic AI Boomi, the data activation company for AI, today announced it has been recognized as aPioneer in the Gartner® Emerging Market Quadrant for No-Code Agent Builders (NCAB). Gartner defines the NCABs market as SaaS-delivered products that offer an integrated design and runtime environment to build, publish and manage AI-powered agents without using coding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615413216/en/ Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders Boomi sees this recognition as a reflection of the company's rapid evolution from an integration and automation powerhouse to a full-scale agentic infrastructure platform, expanding Boomi’s role in the emerging agentic AI market. A New Chapter in Enterprise Agentic AI According to Gartner, vendors recognized as a Pioneer in this quad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
